Invention Grant
- Patent Title: Vascular endothelial growth factor fusion protein
-
Application No.: US15495358Application Date: 2017-04-24
-
Publication No.: US10023627B2Publication Date: 2018-07-17
- Inventor: Daeik Kim , Inra Seo
- Applicant: KOREA PRIME PHARM CO., LTD.
- Applicant Address: KR Gwangju
- Assignee: KOREA PRIME PHARM CO., LTD.
- Current Assignee: KOREA PRIME PHARM CO., LTD.
- Current Assignee Address: KR Gwangju
- Agency: Moser Taboada
- Priority: KR10-2016-0051152 20160426
- Main IPC: C12P21/04
- IPC: C12P21/04 ; C07K14/71 ; A61K38/18 ; A61K39/395 ; C07K14/705 ; A61K38/00 ; C07K14/00

Abstract:
The present invention relates to a fusion protein binding to a vascular endothelial growth factor (VEGFR) and/or a placental growth factor (PIGF). The fusion protein of the present invention comprises (a) a Fc domain of IgG1, wherein two heavy chains are linked by disulfide bond, and (b) four immunoglobulin domain2s of the VEGFR1, wherein two immunoglobulin domain2s are sequentially fused to each heavy chain of the Fc domain of (a). The present fusion protein has excellent activities of inhibiting cell migration and cell invasion, and has highly enhanced growth inhibition effects to various carcinomas and fibroblasts. Therefore, The fusion protein of the present invention can be used in the preparation of an agent for treating cancers or ocular diseases.
Public/Granted literature
- US20170305996A1 VASCULAR ENDOTHELIAL GROWTH FACTOR FUSION PROTEIN Public/Granted day:2017-10-26
Information query